Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LIORESAL vs CARISOPRODOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic reflexes at the spinal cord level by reducing excitatory neurotransmitter release.
Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.
FDA-approved: Intrathecal: severe spasticity of cerebral or spinal origin; Oral: spasticity in multiple sclerosis, spinal cord injury. Off-label: Trigeminal neuralgia, essential tremor, chronic hiccups, alcohol withdrawal, stiff-person syndrome, dystonia, gastroesophageal reflux disease, epilepsy, autism, cluster headaches, intractable hiccups, cocaine dependence, Huntington disease, Tourette syndrome, tardive dyskinesia, periodic limb movement disorder, myoclonus, apraxia of eyelid opening, hemifacial spasm, nystagmus, tic disorders, generalized anxiety disorder, insomnia, and chronic hiccup.
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
Oral: Initial 5 mg 3 times daily, increase by 5 mg per dose every 3 days to a maximum of 80 mg/day (20 mg 4 times daily). Intrathecal: Test dose 50-100 mcg; maintenance infusion 300-800 mcg/day.
250-350 mg orally 3 times daily and at bedtime
Terminal elimination half-life: 2.5-4 hours. Clinically, accumulation occurs in renal impairment, requiring dose adjustment.
Terminal elimination half-life is approximately 2.0 hours for carisoprodol; the active metabolite meprobamate has a half-life of 6-12 hours. Clinical context: Short half-life supports three-times-daily dosing; accumulation of meprobamate with repeated dosing or renal impairment may prolong effects.
Hepatic metabolism via deamination (minor pathway); primarily excreted unchanged in urine (70-80% as parent drug, 15% as metabolites).
Primarily hepatic via CYP2C19; partially metabolized to meprobamate (a Schedule IV controlled substance) by N-dealkylation; also undergoes hydrolysis and subsequent conjugation.
Renal: approximately 70-80% of the dose as unchanged drug and metabolites (primarily glucuronide conjugate); minor biliary/fecal elimination (<5%).
Renal: >99% as metabolites (hydroxycarisoprodol and meprobamate) and minor unchanged drug. Fecal: <1%. Biliary: negligible.
~30%; primarily bound to albumin.
Carisoprodol: approximately 60% bound to plasma proteins (predominantly albumin). Meprobamate: ~20% bound.
0.5-1.0 L/kg; indicates moderate tissue distribution, with higher CNS penetration when administered intrathecally.
Apparent Vd: approximately 0.8 L/kg for carisoprodol (total body water distribution). Clinical meaning: Extensive distribution into tissues; consistent with moderate lipophilicity.
Oral: 70-80% (first-pass effect minimal); intrathecal: nearly 100% due to direct CSF administration.
Oral: Approximately 95% absorbed from the GI tract; extensive first-pass metabolism converts ~50% to meprobamate; net bioavailability of parent drug is ~50-60%.
GFR >60 m L/min: no adjustment; GFR 30-60: reduce dose by 25-50%; GFR <30: avoid or reduce by 75%; hemodialysis: supplement dose after dialysis.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to increased risk of accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A: no dose adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Oral: 2.5 mg 4 times daily initially, increase by 2.5-5 mg every 3 days to max 40 mg/day (2-7 years) or 60 mg/day (8-15 years). Intrathecal: test dose 25-50 mcg; maintenance 100-1000 mcg/day.
Not recommended for use in children under 16 years due to lack of safety and efficacy data.
Start at 5 mg twice daily; increase slowly due to increased CNS sensitivity; monitor for sedation and confusion.
Initiate at 250 mg 3-4 times daily; monitor for sedation and falls; consider reducing dose in frail elderly.
Abrupt discontinuation of intrathecal baclofen may result in life-threatening withdrawal reactions (high fever, altered mental status, severe spasticity, rhabdomyolysis, autonomic dysfunction).
None
Abrupt discontinuation: may cause withdrawal symptoms (hallucinations, seizures, hyperthermia, rebound spasticity). Sedation: may impair ability to drive or operate machinery. Renal impairment: dose adjustment required. Avoid concomitant use with CNS depressants (alcohol, benzodiazepines). Caution in stroke patients, respiratory depression, psychiatric disorders, epilepsy, and pregnancy.
Risk of sedation and dizziness, impairing ability to drive or operate machinery,Potential for abuse and dependence, especially with long-term use; meprobamate is a controlled substance,Withdrawal symptoms including anxiety, insomnia, and seizures upon abrupt discontinuation,Hepatic impairment may alter metabolism; use with caution,May cause serotonin syndrome when used with other serotonergic drugs,Respiratory depression with concurrent use of CNS depressants
Absolute: Hypersensitivity to baclofen or any component; concomitant use of oral baclofen and intrathecal baclofen; intrathecal use contraindicated in patients with IV access device infection, spinal canal obstruction, or bleeding diathesis. Relative: Renal impairment, hepatic impairment, respiratory insufficiency, seizure disorder, history of autonomic dysreflexia, pregnancy, and lactation.
Hypersensitivity to carisoprodol or meprobamate,Acute intermittent porphyria,Concomitant use with MAOIs (potential for hypertensive crisis)
No specific food interactions, but take with or without food consistently to avoid variable absorption.
Avoid alcohol. No specific food interactions known, but CNS depressant effects may be exacerbated by alcohol or other sedating substances.
First trimester: Increased risk of orofacial clefts (cleft palate) based on animal studies and limited human data. Second and third trimesters: Risk of fetal bradycardia, hypotonia, and withdrawal symptoms (irritability, tremors) in neonates. Use only if benefit outweighs risk.
Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: Limited data suggest a possible increased risk of congenital anomalies, particularly with first-trimester exposure. Second and third trimesters: Use may be associated with neonatal withdrawal syndrome including irritability, tremors, and poor feeding. Avoid use during pregnancy, especially during the first trimester.
Lioresal (baclofen) is excreted into human breast milk in low concentrations; M/P ratio is approximately 0.4-0.7. No adverse effects reported in nursing infants. Caution advised, especially in preterm infants or those with renal impairment.
Carisoprodol and its active metabolite meprobamate are excreted into human breast milk. The milk-to-plasma ratio (M/P) is not well established but considered low. However, potential adverse effects in nursing infants include sedation and withdrawal symptoms. The manufacturer recommends caution; avoid breastfeeding while using carisoprodol due to risk of neonatal sedation.
Increased clearance and volume of distribution during pregnancy may require dose adjustments. Dose should be titrated to lowest effective dose, with close monitoring for efficacy and toxicity. No specific dose adjustment guidelines; individualize based on clinical response.
Pharmacokinetic changes during pregnancy (increased volume of distribution, altered hepatic metabolism) may reduce carisoprodol concentrations. However, no specific dose adjustments are recommended due to lack of data and potential fetal risks. Use is not recommended in pregnancy; therefore, dose adjustments are not applicable.
Titrate slowly to avoid sedation and muscle weakness; monitor for withdrawal signs after abrupt discontinuation (e.g., spasticity rebound, hyperpyrexia, seizures). Intrathecal pump requires specialist management.
Carisoprodol is centrally acting muscle relaxant that is metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with history of substance abuse. Use short-term (2-3 weeks) due to lack of evidence for long-term efficacy. Monitor for sedation and dizziness; avoid concomitant use with other CNS depressants. Taper to discontinue after prolonged use to prevent withdrawal symptoms.
Take exactly as prescribed; do not suddenly stop taking this medication.,Avoid alcohol and other CNS depressants.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Report any unusual muscle weakness, confusion, or difficulty breathing.,Keep medication in original container away from moisture and heat.
Take only as prescribed for short-term relief (usually 2-3 weeks).,Do not increase dose or stop abruptly without consulting doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how you react.,Avoid alcohol and other sedatives while taking this medication.,Report any signs of abuse or dependence (e.g., craving, needing higher doses).,Do not share this medication with others due to abuse potential.,Seek medical attention if you experience allergic reactions (rash, itching, swelling) or seizures.
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LIORESAL vs CARISOPRODOL, answered by our medical review team.
LIORESAL is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic reflexes at the spinal cord level by reducing excitatory neurotransmitter release.. CARISOPRODOL is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LIORESAL and CARISOPRODOL depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LIORESAL is: Oral: Initial 5 mg 3 times daily, increase by 5 mg per dose every 3 days to a maximum of 80 mg/day (20 mg 4 times daily). Intrathecal: Test dose 50-100 mcg; maintenance infusion 300-800 mcg/day.. The standard adult dose of CARISOPRODOL is: 250-350 mg orally 3 times daily and at bedtime. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LIORESAL and CARISOPRODOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LIORESAL is classified as Category C. First trimester: Increased risk of orofacial clefts (cleft palate) based on animal studies and limited human data. Second and third trimesters: Risk of fetal bradycardia, hypotonia. CARISOPRODOL is classified as Category A/B. Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.